KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortizatization of Intangibles: 2009-2024

Historic Amortizatization of Intangibles for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $627.3 million.

  • Jazz Pharmaceuticals' Amortizatization of Intangibles rose 6.93% to $168.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.8 million, marking a year-over-year increase of 3.85%. This contributed to the annual value of $627.3 million for FY2024, which is 3.13% up from last year.
  • Jazz Pharmaceuticals' Amortizatization of Intangibles amounted to $627.3 million in FY2024, which was up 3.13% from $608.3 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Amortizatization of Intangibles high stood at $627.3 million for FY2024, and its period low was $259.6 million during FY2020.
  • Over the past 3 years, Jazz Pharmaceuticals' median Amortizatization of Intangibles value was $608.3 million (recorded in 2023), while the average stood at $611.6 million.
  • In the last 5 years, Jazz Pharmaceuticals' Amortizatization of Intangibles dropped by 26.84% in 2020 and then soared by 102.55% in 2021.
  • Jazz Pharmaceuticals' Amortizatization of Intangibles (Yearly) stood at $259.6 million in 2020, then spiked by 102.55% to $525.8 million in 2021, then increased by 13.96% to $599.2 million in 2022, then climbed by 1.52% to $608.3 million in 2023, then grew by 3.13% to $627.3 million in 2024.